Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) said members of its products, medical affairs, government and public affairs teams will participate in four international preparedness conferences in April–June 2026.
Conferences listed include London Defence Conference (April 10–11), CBRN Research & Innovation (May 19–21), Global Health Security (June 9–12) and BIO International Convention (June 20–22). The company emphasized collaboration with governments on medical countermeasures for threats such as smallpox, anthrax, botulism and Ebola.
Positive
- None.
Negative
- None.
News Market Reaction – EBS
In the Apr 2 session, EBS declined 1.79%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Government contracts | Positive | -1.6% | Over $60M in U.S. and international smallpox countermeasure contracts. |
| Mar 03 | Board appointment | Positive | -0.8% | Appointment of John D. Fowler Jr. to the board and audit committee. |
| Feb 26 | Earnings results | Positive | -26.6% | Q4 and FY2025 results with $742.9M revenue and $52.6M net income. |
| Feb 26 | Share repurchase | Positive | -26.6% | New $50M stock repurchase program replacing prior authorization. |
| Feb 26 | Government contracts | Positive | -26.6% | Canadian contracts and modification valued up to ~CAD 140M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or strategic news (contracts, buybacks, governance) has often been followed by negative next-day price reactions, suggesting a pattern of downside divergence after bullish headlines.
Over recent months, EBS reported sizeable government contracts and stockholder-focused actions. On Feb 26, earnings showed FY2025 revenue of $742.9M, net income of $52.6M, and a new $50M buyback, yet the stock fell about 26.6%. Subsequent Canadian and U.S. government contract wins, including over $60M for smallpox countermeasures, also saw modest declines. Against that backdrop, today’s conference-participation update is relatively low impact and more about visibility than new financial commitments.
Key Terms
cbrn technical
biodefense medical
medical countermeasures medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences:
- London Defence Conference, April 10-11, London, United Kingdom
- CBRN Research & Innovation Conference, May 19-21, Arcachon, France
- Global Health Security Conference, June 9-12, Kuala Lumpur, Malaysia
- BIO International Convention, June 20-22, San Diego, California, United States
“As the world navigates an increasingly complex health threat landscape, Emergent is committed to working with governments to help protect regional and global security,” said Paul Williams, senior vice president, head of products business, global government and public affairs. “We look forward to engaging with government and industry leaders to discuss how together we can strengthen preparedness and help protect and save lives.”
Emergent specializes in developing, manufacturing and delivering medical countermeasures to governments around the world for security and preparedness. These products support emergency response preparedness and help protect the public from critical threats like smallpox, anthrax, botulism and Ebola. Learn more about how we help protect people worldwide from biological threats at emergentbiosolutions.com/biothreats.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
